Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial.

Janin ChandraWai-Ping WooJulie L DuttonYan XuBo LiSally KinradeJulian DruceNeil FinlaysonPaul GriffinKerry J LaingDavid M KoelleIan Hector Frazer

Published in: PloS one (2019)

This study confirms the previously demonstrated safety of COR-1 in humans and indicates a potential for use of COR-1 as a therapy to reduce viral shedding in HSV-2 infected subjects.

Keyphrases

herpes simplex virus
immune response
clinical trial
sars cov
study protocol
phase iii
stem cells
toll like receptor
randomized controlled trial
dendritic cells
risk assessment
mesenchymal stem cells
human health
climate change
bone marrow
smoking cessation